Global Preimplantation Genetics Diagnosis Market

Preimplantation Genetics Diagnosis Comprehensive Study by Type (Instrument, Reagent), Application (HLA Typing, Inheritable Genetic Disorders, Chromosomal Abnormalities, Single Gene Disorders, Gender Identification, Sex Linked Disorders), Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescence In-situ Hybridization (FISH), Comparative Genomic Hybridization (CGH)), End User (Hospital, Diagnostic Lab, Research Lab, Academia) Players and Region - Global Market Outlook to 2026

Preimplantation Genetics Diagnosis Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Preimplantation Genetics Diagnosis
Pre-implantation genetic diagnosis (PGD) is a genetic analysis of the embryo that is performed by studying a biopsy of its cells prior to transfer to the mother's uterus. The high demand for PGD is to ensure that children are healthy and put an end to the transmission of a specific condition. PGD help to study the genetic diseases affecting a single gene and its use is not questioned. It is the only means of avoiding transmission of a genetic disorder without the partner having to face the possibility of the child she is carrying being affected and, therefore, having to face the decision of terminating the pregnancy.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The rising number of players in the global market is predicted to enhance the competition level as well as encourage the growth of the overall market in the near future. There are various companies that are operating in the new geographical regions by adopting various market growth initiatives such as mergers & acquisitions, expansions, investments, and others. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Preimplantation Genetics Diagnosis market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abbott Laboratories (United States), Natera, Inc (United States), Genea Limited (Australia), PerkinElmer, Inc. (United States), Illumina, Inc.(United States), F. Hoffmann-La Roche AG (Switzerland), Thermo Fisher Scientific (United States), Laboratory Corporation of America Holdings (United States), Agilent Technologies (United States), Quest Diagnostics Incorporated (United States), Cooper Surgical (United States) and Beijing Genomics Institute (BGI) (China) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Reproductive Genetics Institute (United States) and Reprogenetics LLC (United States).

Segmentation Overview
AMA Research has segmented the market of Global Preimplantation Genetics Diagnosis market by Type (Instrument and Reagent), Application (HLA Typing, Inheritable Genetic Disorders, Chromosomal Abnormalities, Single Gene Disorders, Gender Identification and Sex Linked Disorders) and Region.



On the basis of geography, the market of Preimplantation Genetics Diagnosis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Technology, the sub-segment i.e. Polymerase Chain Reaction (PCR) will boost the Preimplantation Genetics Diagnosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital will boost the Preimplantation Genetics Diagnosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancements in the Field of Genetic Analysis and Growing Demand for Non-invasive Biopsy Procedures in PGD

Market Growth Drivers:
Increasing Rate of Infertility and Growing Awareness related to Genetic Techniques

Challenges:
Unfavorable Government Regulations associated with Preimplantation Genetic Diagnosis

Restraints:
High Cost of Treatment

Opportunities:
Surging R&D in Genetics by Key Players and Improving Healthcare Infrastructure in Developing Countries

Market Leaders and their expansionary development strategies
In Jun 2020, Natera, Inc., a pioneer and global leader in cell-free DNA testing is pleased to announce the expansion of its laboratory facility in Austin, Texas, supporting greater test processing capacity.
In Oct 2018, Vitrolife AB (publ) has entered into a License and Commercialisation Agreement with Illumina, Inc., which provides Vitrolife with exclusive distribution, development, and commercialization rights to Illumina’s preimplantation genetic testing business for IVF in EMEA and Americas.


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Preimplantation Genetic Diagnosis Providers, Government Regulatory and Research Organizations and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Instrument
  • Reagent
By Application
  • HLA Typing
  • Inheritable Genetic Disorders
  • Chromosomal Abnormalities
  • Single Gene Disorders
  • Gender Identification
  • Sex Linked Disorders
By Technology
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Fluorescence In-situ Hybridization (FISH)
  • Comparative Genomic Hybridization (CGH)

By End User
  • Hospital
  • Diagnostic Lab
  • Research Lab
  • Academia

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Rate of Infertility
      • 3.2.2. Growing Awareness related to Genetic Techniques
    • 3.3. Market Challenges
      • 3.3.1. Unfavorable Government Regulations associated with Preimplantation Genetic Diagnosis
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in the Field of Genetic Analysis
      • 3.4.2. Growing Demand for Non-invasive Biopsy Procedures in PGD
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Preimplantation Genetics Diagnosis, by Type, Application, Technology, End User and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Preimplantation Genetics Diagnosis (Value)
      • 5.2.1. Global Preimplantation Genetics Diagnosis by: Type (Value)
        • 5.2.1.1. Instrument
        • 5.2.1.2. Reagent
      • 5.2.2. Global Preimplantation Genetics Diagnosis by: Application (Value)
        • 5.2.2.1. HLA Typing
        • 5.2.2.2. Inheritable Genetic Disorders
        • 5.2.2.3. Chromosomal Abnormalities
        • 5.2.2.4. Single Gene Disorders
        • 5.2.2.5. Gender Identification
        • 5.2.2.6. Sex Linked Disorders
      • 5.2.3. Global Preimplantation Genetics Diagnosis by: Technology (Value)
        • 5.2.3.1. Polymerase Chain Reaction (PCR)
        • 5.2.3.2. Next-Generation Sequencing (NGS)
        • 5.2.3.3. Fluorescence In-situ Hybridization (FISH)
        • 5.2.3.4. Comparative Genomic Hybridization (CGH)
      • 5.2.4. Global Preimplantation Genetics Diagnosis by: End User (Value)
        • 5.2.4.1. Hospital
        • 5.2.4.2. Diagnostic Lab
        • 5.2.4.3. Research Lab
        • 5.2.4.4. Academia
      • 5.2.5. Global Preimplantation Genetics Diagnosis Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Preimplantation Genetics Diagnosis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Natera, Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Genea Limited (Australia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. PerkinElmer, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Illumina, Inc.(United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Thermo Fisher Scientific (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Laboratory Corporation of America Holdings (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Agilent Technologies (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Quest Diagnostics Incorporated (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Cooper Surgical (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Beijing Genomics Institute (BGI) (China)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Preimplantation Genetics Diagnosis Sale, by Type, Application, Technology, End User and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Preimplantation Genetics Diagnosis (Value)
      • 7.2.1. Global Preimplantation Genetics Diagnosis by: Type (Value)
        • 7.2.1.1. Instrument
        • 7.2.1.2. Reagent
      • 7.2.2. Global Preimplantation Genetics Diagnosis by: Application (Value)
        • 7.2.2.1. HLA Typing
        • 7.2.2.2. Inheritable Genetic Disorders
        • 7.2.2.3. Chromosomal Abnormalities
        • 7.2.2.4. Single Gene Disorders
        • 7.2.2.5. Gender Identification
        • 7.2.2.6. Sex Linked Disorders
      • 7.2.3. Global Preimplantation Genetics Diagnosis by: Technology (Value)
        • 7.2.3.1. Polymerase Chain Reaction (PCR)
        • 7.2.3.2. Next-Generation Sequencing (NGS)
        • 7.2.3.3. Fluorescence In-situ Hybridization (FISH)
        • 7.2.3.4. Comparative Genomic Hybridization (CGH)
      • 7.2.4. Global Preimplantation Genetics Diagnosis by: End User (Value)
        • 7.2.4.1. Hospital
        • 7.2.4.2. Diagnostic Lab
        • 7.2.4.3. Research Lab
        • 7.2.4.4. Academia
      • 7.2.5. Global Preimplantation Genetics Diagnosis Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Preimplantation Genetics Diagnosis: by Type(USD Million)
  • Table 2. Preimplantation Genetics Diagnosis Instrument , by Region USD Million (2016-2021)
  • Table 3. Preimplantation Genetics Diagnosis Reagent , by Region USD Million (2016-2021)
  • Table 4. Preimplantation Genetics Diagnosis: by Application(USD Million)
  • Table 5. Preimplantation Genetics Diagnosis HLA Typing , by Region USD Million (2016-2021)
  • Table 6. Preimplantation Genetics Diagnosis Inheritable Genetic Disorders , by Region USD Million (2016-2021)
  • Table 7. Preimplantation Genetics Diagnosis Chromosomal Abnormalities , by Region USD Million (2016-2021)
  • Table 8. Preimplantation Genetics Diagnosis Single Gene Disorders , by Region USD Million (2016-2021)
  • Table 9. Preimplantation Genetics Diagnosis Gender Identification , by Region USD Million (2016-2021)
  • Table 10. Preimplantation Genetics Diagnosis Sex Linked Disorders , by Region USD Million (2016-2021)
  • Table 11. Preimplantation Genetics Diagnosis: by Technology(USD Million)
  • Table 12. Preimplantation Genetics Diagnosis Polymerase Chain Reaction (PCR) , by Region USD Million (2016-2021)
  • Table 13. Preimplantation Genetics Diagnosis Next-Generation Sequencing (NGS) , by Region USD Million (2016-2021)
  • Table 14. Preimplantation Genetics Diagnosis Fluorescence In-situ Hybridization (FISH) , by Region USD Million (2016-2021)
  • Table 15. Preimplantation Genetics Diagnosis Comparative Genomic Hybridization (CGH) , by Region USD Million (2016-2021)
  • Table 16. Preimplantation Genetics Diagnosis: by End User(USD Million)
  • Table 17. Preimplantation Genetics Diagnosis Hospital , by Region USD Million (2016-2021)
  • Table 18. Preimplantation Genetics Diagnosis Diagnostic Lab , by Region USD Million (2016-2021)
  • Table 19. Preimplantation Genetics Diagnosis Research Lab , by Region USD Million (2016-2021)
  • Table 20. Preimplantation Genetics Diagnosis Academia , by Region USD Million (2016-2021)
  • Table 21. South America Preimplantation Genetics Diagnosis, by Country USD Million (2016-2021)
  • Table 22. South America Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 23. South America Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 24. South America Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 25. South America Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 26. Brazil Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 27. Brazil Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 28. Brazil Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 29. Brazil Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 30. Argentina Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 31. Argentina Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 32. Argentina Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 33. Argentina Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 34. Rest of South America Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 35. Rest of South America Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 36. Rest of South America Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 37. Rest of South America Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 38. Asia Pacific Preimplantation Genetics Diagnosis, by Country USD Million (2016-2021)
  • Table 39. Asia Pacific Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 40. Asia Pacific Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 41. Asia Pacific Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 42. Asia Pacific Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 43. China Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 44. China Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 45. China Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 46. China Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 47. Japan Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 48. Japan Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 49. Japan Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 50. Japan Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 51. India Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 52. India Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 53. India Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 54. India Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 55. South Korea Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 56. South Korea Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 57. South Korea Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 58. South Korea Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 59. Taiwan Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 60. Taiwan Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 61. Taiwan Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 62. Taiwan Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 63. Australia Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 64. Australia Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 65. Australia Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 66. Australia Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 70. Rest of Asia-Pacific Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 71. Europe Preimplantation Genetics Diagnosis, by Country USD Million (2016-2021)
  • Table 72. Europe Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 73. Europe Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 74. Europe Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 75. Europe Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 76. Germany Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 77. Germany Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 78. Germany Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 79. Germany Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 80. France Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 81. France Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 82. France Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 83. France Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 84. Italy Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 85. Italy Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 86. Italy Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 87. Italy Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 88. United Kingdom Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 89. United Kingdom Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 90. United Kingdom Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 91. United Kingdom Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 92. Netherlands Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 93. Netherlands Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 94. Netherlands Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 95. Netherlands Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 96. Rest of Europe Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 97. Rest of Europe Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 98. Rest of Europe Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 99. Rest of Europe Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 100. MEA Preimplantation Genetics Diagnosis, by Country USD Million (2016-2021)
  • Table 101. MEA Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 102. MEA Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 103. MEA Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 104. MEA Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 105. Middle East Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 106. Middle East Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 107. Middle East Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 108. Middle East Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 109. Africa Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 110. Africa Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 111. Africa Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 112. Africa Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 113. North America Preimplantation Genetics Diagnosis, by Country USD Million (2016-2021)
  • Table 114. North America Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 115. North America Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 116. North America Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 117. North America Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 118. United States Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 119. United States Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 120. United States Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 121. United States Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 122. Canada Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 123. Canada Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 124. Canada Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 125. Canada Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 126. Mexico Preimplantation Genetics Diagnosis, by Type USD Million (2016-2021)
  • Table 127. Mexico Preimplantation Genetics Diagnosis, by Application USD Million (2016-2021)
  • Table 128. Mexico Preimplantation Genetics Diagnosis, by Technology USD Million (2016-2021)
  • Table 129. Mexico Preimplantation Genetics Diagnosis, by End User USD Million (2016-2021)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Preimplantation Genetics Diagnosis: by Type(USD Million)
  • Table 143. Preimplantation Genetics Diagnosis Instrument , by Region USD Million (2022-2027)
  • Table 144. Preimplantation Genetics Diagnosis Reagent , by Region USD Million (2022-2027)
  • Table 145. Preimplantation Genetics Diagnosis: by Application(USD Million)
  • Table 146. Preimplantation Genetics Diagnosis HLA Typing , by Region USD Million (2022-2027)
  • Table 147. Preimplantation Genetics Diagnosis Inheritable Genetic Disorders , by Region USD Million (2022-2027)
  • Table 148. Preimplantation Genetics Diagnosis Chromosomal Abnormalities , by Region USD Million (2022-2027)
  • Table 149. Preimplantation Genetics Diagnosis Single Gene Disorders , by Region USD Million (2022-2027)
  • Table 150. Preimplantation Genetics Diagnosis Gender Identification , by Region USD Million (2022-2027)
  • Table 151. Preimplantation Genetics Diagnosis Sex Linked Disorders , by Region USD Million (2022-2027)
  • Table 152. Preimplantation Genetics Diagnosis: by Technology(USD Million)
  • Table 153. Preimplantation Genetics Diagnosis Polymerase Chain Reaction (PCR) , by Region USD Million (2022-2027)
  • Table 154. Preimplantation Genetics Diagnosis Next-Generation Sequencing (NGS) , by Region USD Million (2022-2027)
  • Table 155. Preimplantation Genetics Diagnosis Fluorescence In-situ Hybridization (FISH) , by Region USD Million (2022-2027)
  • Table 156. Preimplantation Genetics Diagnosis Comparative Genomic Hybridization (CGH) , by Region USD Million (2022-2027)
  • Table 157. Preimplantation Genetics Diagnosis: by End User(USD Million)
  • Table 158. Preimplantation Genetics Diagnosis Hospital , by Region USD Million (2022-2027)
  • Table 159. Preimplantation Genetics Diagnosis Diagnostic Lab , by Region USD Million (2022-2027)
  • Table 160. Preimplantation Genetics Diagnosis Research Lab , by Region USD Million (2022-2027)
  • Table 161. Preimplantation Genetics Diagnosis Academia , by Region USD Million (2022-2027)
  • Table 162. South America Preimplantation Genetics Diagnosis, by Country USD Million (2022-2027)
  • Table 163. South America Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 164. South America Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 165. South America Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 166. South America Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 167. Brazil Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 168. Brazil Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 169. Brazil Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 170. Brazil Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 171. Argentina Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 172. Argentina Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 173. Argentina Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 174. Argentina Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 175. Rest of South America Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 176. Rest of South America Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 177. Rest of South America Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 178. Rest of South America Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 179. Asia Pacific Preimplantation Genetics Diagnosis, by Country USD Million (2022-2027)
  • Table 180. Asia Pacific Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 181. Asia Pacific Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 182. Asia Pacific Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 183. Asia Pacific Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 184. China Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 185. China Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 186. China Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 187. China Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 188. Japan Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 189. Japan Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 190. Japan Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 191. Japan Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 192. India Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 193. India Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 194. India Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 195. India Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 196. South Korea Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 197. South Korea Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 198. South Korea Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 199. South Korea Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 200. Taiwan Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 201. Taiwan Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 202. Taiwan Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 203. Taiwan Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 204. Australia Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 205. Australia Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 206. Australia Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 207. Australia Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 208. Rest of Asia-Pacific Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 209. Rest of Asia-Pacific Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 210. Rest of Asia-Pacific Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 211. Rest of Asia-Pacific Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 212. Europe Preimplantation Genetics Diagnosis, by Country USD Million (2022-2027)
  • Table 213. Europe Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 214. Europe Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 215. Europe Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 216. Europe Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 217. Germany Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 218. Germany Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 219. Germany Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 220. Germany Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 221. France Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 222. France Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 223. France Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 224. France Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 225. Italy Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 226. Italy Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 227. Italy Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 228. Italy Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 229. United Kingdom Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 230. United Kingdom Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 231. United Kingdom Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 232. United Kingdom Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 233. Netherlands Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 234. Netherlands Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 235. Netherlands Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 236. Netherlands Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 237. Rest of Europe Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 238. Rest of Europe Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 239. Rest of Europe Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 240. Rest of Europe Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 241. MEA Preimplantation Genetics Diagnosis, by Country USD Million (2022-2027)
  • Table 242. MEA Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 243. MEA Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 244. MEA Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 245. MEA Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 246. Middle East Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 247. Middle East Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 248. Middle East Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 249. Middle East Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 250. Africa Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 251. Africa Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 252. Africa Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 253. Africa Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 254. North America Preimplantation Genetics Diagnosis, by Country USD Million (2022-2027)
  • Table 255. North America Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 256. North America Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 257. North America Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 258. North America Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 259. United States Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 260. United States Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 261. United States Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 262. United States Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 263. Canada Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 264. Canada Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 265. Canada Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 266. Canada Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 267. Mexico Preimplantation Genetics Diagnosis, by Type USD Million (2022-2027)
  • Table 268. Mexico Preimplantation Genetics Diagnosis, by Application USD Million (2022-2027)
  • Table 269. Mexico Preimplantation Genetics Diagnosis, by Technology USD Million (2022-2027)
  • Table 270. Mexico Preimplantation Genetics Diagnosis, by End User USD Million (2022-2027)
  • Table 271. Research Programs/Design for This Report
  • Table 272. Key Data Information from Secondary Sources
  • Table 273. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Preimplantation Genetics Diagnosis: by Type USD Million (2016-2021)
  • Figure 5. Global Preimplantation Genetics Diagnosis: by Application USD Million (2016-2021)
  • Figure 6. Global Preimplantation Genetics Diagnosis: by Technology USD Million (2016-2021)
  • Figure 7. Global Preimplantation Genetics Diagnosis: by End User USD Million (2016-2021)
  • Figure 8. South America Preimplantation Genetics Diagnosis Share (%), by Country
  • Figure 9. Asia Pacific Preimplantation Genetics Diagnosis Share (%), by Country
  • Figure 10. Europe Preimplantation Genetics Diagnosis Share (%), by Country
  • Figure 11. MEA Preimplantation Genetics Diagnosis Share (%), by Country
  • Figure 12. North America Preimplantation Genetics Diagnosis Share (%), by Country
  • Figure 13. Global Preimplantation Genetics Diagnosis share by Players 2021 (%)
  • Figure 14. Global Preimplantation Genetics Diagnosis share by Players (Top 3) 2021(%)
  • Figure 15. Global Preimplantation Genetics Diagnosis share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2021
  • Figure 19. Natera, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 20. Natera, Inc (United States) Revenue: by Geography 2021
  • Figure 21. Genea Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 22. Genea Limited (Australia) Revenue: by Geography 2021
  • Figure 23. PerkinElmer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. PerkinElmer, Inc. (United States) Revenue: by Geography 2021
  • Figure 25. Illumina, Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 26. Illumina, Inc.(United States) Revenue: by Geography 2021
  • Figure 27. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2021
  • Figure 29. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 30. Thermo Fisher Scientific (United States) Revenue: by Geography 2021
  • Figure 31. Laboratory Corporation of America Holdings (United States) Revenue, Net Income and Gross profit
  • Figure 32. Laboratory Corporation of America Holdings (United States) Revenue: by Geography 2021
  • Figure 33. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 34. Agilent Technologies (United States) Revenue: by Geography 2021
  • Figure 35. Quest Diagnostics Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 36. Quest Diagnostics Incorporated (United States) Revenue: by Geography 2021
  • Figure 37. Cooper Surgical (United States) Revenue, Net Income and Gross profit
  • Figure 38. Cooper Surgical (United States) Revenue: by Geography 2021
  • Figure 39. Beijing Genomics Institute (BGI) (China) Revenue, Net Income and Gross profit
  • Figure 40. Beijing Genomics Institute (BGI) (China) Revenue: by Geography 2021
  • Figure 41. Global Preimplantation Genetics Diagnosis: by Type USD Million (2022-2027)
  • Figure 42. Global Preimplantation Genetics Diagnosis: by Application USD Million (2022-2027)
  • Figure 43. Global Preimplantation Genetics Diagnosis: by Technology USD Million (2022-2027)
  • Figure 44. Global Preimplantation Genetics Diagnosis: by End User USD Million (2022-2027)
  • Figure 45. South America Preimplantation Genetics Diagnosis Share (%), by Country
  • Figure 46. Asia Pacific Preimplantation Genetics Diagnosis Share (%), by Country
  • Figure 47. Europe Preimplantation Genetics Diagnosis Share (%), by Country
  • Figure 48. MEA Preimplantation Genetics Diagnosis Share (%), by Country
  • Figure 49. North America Preimplantation Genetics Diagnosis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Natera, Inc (United States)
  • Genea Limited (Australia)
  • PerkinElmer, Inc. (United States)
  • Illumina, Inc.(United States)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Thermo Fisher Scientific (United States)
  • Laboratory Corporation of America Holdings (United States)
  • Agilent Technologies (United States)
  • Quest Diagnostics Incorporated (United States)
  • Cooper Surgical (United States)
  • Beijing Genomics Institute (BGI) (China)
Additional players considered in the study are as follows:
Reproductive Genetics Institute (United States) , Reprogenetics LLC (United States)
Select User Access Type

Key Highlights of Report


Feb 2021 208 Pages 76 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Preimplantation Genetics Diagnosis Market Quantitative research analysis
Global Preimplantation Genetics Diagnosis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Abbott Laboratories (United States), Natera, Inc (United States), Genea Limited (Australia), PerkinElmer, Inc. (United States), Illumina, Inc.(United States), F. Hoffmann-La Roche AG (Switzerland), Thermo Fisher Scientific (United States), Laboratory Corporation of America Holdings (United States), Agilent Technologies (United States), Quest Diagnostics Incorporated (United States), Cooper Surgical (United States) and Beijing Genomics Institute (BGI) (China) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Advancements in the Field of Genetic Analysis " is seen as one of major influencing trends for Preimplantation Genetics Diagnosis Market during projected period 2021-2027.
The Preimplantation Genetics Diagnosis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Preimplantation Genetics Diagnosis Market Report?

Have a Query? Click Here

Other Related Reports

Blood Products Comprehensive Study by Type (Whole Blood Collection (System and Reagents), Source Plasma Collection (System and Reagents), Blood Therapeutics (IVIG, Albumin, Factor VIII, XI and Others...
$ 3650
Wound Care Biologics Comprehensive Study by Type (Biologic Skin Substitutes (Human Donor Tissue-derived Products, Acellular animal-derived Products, Biosynthetic Products), Topical Agents), Wound (Ul...
$ 3750
Pneumonia Therapeutics Comprehensive Study by Type (Vaccines, Anti-Infectives, Oxygen Therapy), Application (Hospital, Clinic, Medical Center, Other), Pneumonia Types (Hospital-acquired pneumonia (HA...
$ 3650
Bone Morphogenetic Protein Comprehensive Study by Type (Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2, Recombinant Human Bone Morphogenetic Protein (rhBMP) -7), Application (Spinal Fusion,...
$ 3350
Spasticity Treatment Comprehensive Study by Type (Physical Treatment, Medicine Treatment), Application (Children, Adults), End User (Hospital, Research Laboratories, Others) Players and Region - Glob...
$ 3500
Tuberculosis Drug Comprehensive Study by Type (First-line Anti-TB Drugs, Second-line Anti-TB Drugs), Application (Active TB, Latent TB), End User (Hospital, Clinic, Durgstore), Testing (TB skin test ...
$ 3350